What is HC Wainwright’s Forecast for CAPR Q1 Earnings?

Capricor Therapeutics Inc (NASDAQ:CAPR) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Capricor Therapeutics in a research report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings per share of ($0.35) for the quarter. HC Wainwright has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q3 2025 earnings at $0.94 EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at ($0.61) EPS.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Price Performance

CAPR stock opened at $13.48 on Monday. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The stock has a market cap of $612.94 million, a price-to-earnings ratio of -12.72 and a beta of 4.10. The company has a fifty day moving average price of $14.09 and a two-hundred day moving average price of $14.83.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of the business. Summit Investment Advisors Inc. raised its stake in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $68,000. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund grew its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after buying an additional 5,000 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.